Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.85 |
| ▸ | CHAT | P28329 | 2/20 | 0.79 |
| ▸ | EP300 | Q09472 | 4/20 | 0.78 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.78 |
| ▸ | AURKA | O14965 | 1/20 | 0.78 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.78 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29632807 | 1.00 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL18327200 | 1.00 | NAA50 (0.85) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL28887972 | 0.95 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL21327973 | 0.95 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL16428887 | 0.95 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL29849789 | 0.95 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL29238963 | 0.95 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL30221151 | 0.95 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL16018847 | 0.95 | NAA50 (0.89) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL20211012 | 0.95 | NAA50 (0.89) | NAA50CHATEP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713320-A2 | BCAT2 INHIBITORS | Agios Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-20260022407-A1 | METHOD, ENZYME COMPOSITION, NUCLEIC ACID COMPOSITION, AND TRANSGENIC MICROORGANISM FOR PRODUCING ISOPRENE GLYCOL | NATIONAL YANG MING CHIAO TUNG UNIV (TW) | 2026-01-22 | — | — | US | claimed |
| US-12497635-B2 | Means and methods for producing isobutene from acetyl-CoA | GLOBAL BIOENERGIES (FR) | 2025-12-16 | — | — | US | claimed |
| US-12460234-B2 | Synthesis of isoprenoids and derivatives | WILLIAM MARSH RICE UNIVERSITY (US) | 2025-11-04 | — | — | US | claimed |
| US-20250327097-A1 | ORGANISMS PRODUCING LESS CROTONIC ACID | GLOBAL BIOENERGIES (FR) | 2025-10-23 | — | — | US | claimed |
| WO-2024238820-A2 | BCAT2 INHIBITORS | AGIOS PHARMACEUTICALS, INC. (US) | 2024-11-21 | — | — | WO | claimed |
| US-20240366543-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | HEMOSHEAR THERAPEUTICS INC (US) | 2024-11-07 | — | — | US | claimed |
| EP-4430036-A2 | BCAT2 INHIBITORS | Agios Pharmaceuticals, Inc. (US) | 2024-09-18 | — | — | EP | claimed |
| EP-4399284-A1 | ORGANISMS PRODUCING LESS CROTONIC ACID | Global Bioenergies (FR) | 2024-07-17 | — | — | EP | claimed |
| EP-4319746-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | Hemoshear Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | claimed |
| EP-3189130-A1 | RECOMBINANT MICROORGANISM PRODUCING ALKENES FROM ACETYL-COA | Global Bioenergies (FR) | 2017-07-12 | — | — | EP | claimed |
| US-20170051314-A1 | METHODS, CELLS AND REAGENTS FOR PRODUCTION OF ISOPRENE, DERIVATIVES AND INTERMEDIATES THEREOF | INVISTA North America S.à.r.l. | 2017-02-23 | — | — | US | claimed |
| WO-2017029553-A2 | METHODS, CELLS AND REAGENTS FOR PRODUCTION OF ISOPRENE, DERIVATIVES AND INTERMEDIATES THEREOF | CONRADIE ALEX VAN ECK (GB) | 2017-02-23 | — | — | WO | claimed |
| WO-2016207267-A1 | METHOD FOR THE PRODUCTION OF ISOAMYL ALCOHOL | GLOBAL BIOENERGIES (FR) | 2016-12-29 | — | — | WO | claimed |
| US-9410164-B2 | Biosynthesis pathway for prenol in a recombinant microorganism | METABOLIC EXPLORER (FR) | 2016-08-09 | — | — | US | claimed |
| WO-2016034691-A1 | RECOMBINANT MICROORGANISM PRODUCING ALKENES FROM ACETYL-COA | SYNGIP BV (NL) | 2016-03-10 | — | — | WO | claimed |
| US-20140256008-A1 | NEW BIOSYNTHESIS PATHWAY FOR PRENOL IN A RECOMBINANT MICROORGANISM | METABOLIC EXPLORER (FR) | 2014-09-11 | — | — | US | claimed |
| EP-2766492-A1 | NEW BIOSYNTHESIS PATHWAY FOR PRENOL IN A RECOMBINANT MICROORGANISM | Metabolic Explorer (FR) | 2014-08-20 | — | — | EP | claimed |
| WO-2013053824-A1 | NEW BIOSYNTHESIS PATHWAY FOR PRENOL IN A RECOMBINANT MICROORGANISM | METABOLIC EXPLORER (FR) | 2013-04-18 | — | — | WO | claimed |
| WO-2009064910-A2 | DIMETHYLOCTANE AS AN ADVANCED BIOFUEL | SYNTHETIC GENOMICS, INC. (US) | 2009-05-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022407-A1 | METHOD, ENZYME COMPOSITION, NUCLEIC ACID COMPOSITION, AND TRANSGENIC MICROORGANISM FOR PRODUCING ISOPRENE GLYCOL | ACACB, ACACA, HMGCR | NAA50 448/4885CHAT 213/4885EP300 693/4885 |
| US-20240366543-A1 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | MMAB, OTC, ME2 | NAA50 3556/4885CHAT 1146/4885EP300 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.